Edition:
United Kingdom

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

4.00USD
22 Jun 2018
Change (% chg)

$-0.05 (-1.23%)
Prev Close
$4.05
Open
$4.05
Day's High
$4.05
Day's Low
$3.92
Volume
69,754
Avg. Vol
64,448
52-wk High
$5.75
52-wk Low
$1.58

Select another date:

Thu, May 24 2018

BRIEF-AcelRx Announces FDA Acceptance Of NDA For Dsuvia

* ACELRX PHARMACEUTICALS INC - DSUVIA PDUFA DATE SET FOR NOVEMBER 3, 2018

BRIEF-Three Arch's Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry Ventures

* THREE ARCH'S SHARES OF ACELRX COMMON STOCK ACQUIRED IN A PRIVATE TRANSACTION LED BY LEERINK REVELATION PARTNERS AND INDUSTRY VENTURES

BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23

* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Acelrx Resubmits New Drug Application For Dsuvia

* ACELRX PHARMACEUTICALS INC - EXPECTS A SIX-MONTH REVIEW BY FDA WITH A PROJECTED PDUFA DATE IN Q4 2018

BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings

* ACELRX RECEIVES POSITIVE CHMP OPINION FOR DZUVEO™ FOR MANAGEMENT OF ACUTE MODERATE TO SEVERE PAIN IN MEDICALLY MONITORED SETTINGS

BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA

* ACELRX ANNOUNCES COMPLETION OF THE HUMAN FACTORS STUDY FOR DSUVIA AND CONFIRMS PLANS TO RESUBMIT NDA IN Q2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-AcelRx Pharma Q4 Loss Per Share $0.20

* ACELRX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-AcelRX Plans To Resubmit The Dsuvia New Drug Application In Q2

* ACELRX ANNOUNCES RECEIPT OF TYPE A FDA MEETING MINUTES AND PLANS TO RESUBMIT THE DSUVIA NEW DRUG APPLICATION IN Q2 2018

Select another date: